Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Medicus Pharma Ltd.

NASDAQ: MDCX · Life Sciences · 7 alerts · CIK 1997296

Share price
$1.69Close, Nov 16
Market cap
$3.25M
Shares outstanding
1.92MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Medicus Pharma Ltd. filings on SEC EDGAR ↗

7:31 AM ET 8-K
Capital Raise

Medicus Pharma Capital Raise of $3M

Medicus Pharma Ltd. entered into a securities purchase agreement for a registered direct offering of 97,973 common shares and 1,646,213 pre-funded warrants for gross proceeds of approximately $3.0 million. Additionally, the company executed a debt-for-equity exchange with Streeterville Capital, LLC, partitioning $10.5 million in principal from an existing secured promissory note into 105,000 non-convertible preferred shares to reduce its debt obligations.

Value
$3M
4:07 PM ET 10-Q
Financial Results

Medicus Pharma Q3 2026 Results: Net Loss of $15.2M, Loss Narrows

Medicus Pharma Ltd. reported a net loss of $35.9 million for the nine months ended September 30, 2026, driven by $10 million in IPR&D charges and increased R&D spending. The company significantly strengthened its cash position through $17.2 million in ATM proceeds and $22 million from debentures, though it maintains a total shareholders' deficit of $10.5 million.

Key figure
Net loss $15.2M
5:31 PM ET 8-K
M&A Deal

Medicus Pharma Announces $135M M&A Deal

Medicus Pharma announced that its wholly-owned subsidiary, SkinJect, Inc., has entered into a non-binding letter of intent for a business combination with an undisclosed SPAC. The proposed transaction contemplates a $135 million pre-money enterprise valuation for SkinJect and is expected to close in the first half of 2027, with Medicus seeking to retain majority ownership.

Value
$135M

“We believe this proposed transaction will represent a meaningful step toward executing our strategic mandate to unlock the value of this important clinical-stage asset for our shareholders. The proposed transaction, in addition to establishing an independent public-market platform and access for Skinject, will also allow Medicus to participate in its future growth”

Dr. Raza Bokhari, Medicus Exec. Chairman and CEO
5:15 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Medicus Pharma Nasdaq/NYSE Compliance Notice

Medicus Pharma Ltd. regained compliance with Nasdaq's $1.00 minimum bid price requirement after its common shares closed at or above $1.00 for ten consecutive business days. This compliance notice supersedes a delisting determination letter received on October 20, 2026, which had initially triggered a delisting process due to the company's failure to meet the bid price and stockholders' equity requirements.

Counterparty
Nasdaq
4:56 PM ET 8-K
Reverse Stock Split

Medicus Pharma Reverse Stock Split

Medicus Pharma Ltd. implemented a 1-for-50 reverse stock split (share consolidation) of its common shares effective October 12, 2026. The consolidation was previously approved by shareholders at the June 2026 annual meeting and is intended to adjust the company's share count and price on The Nasdaq Capital Market.

4:06 PM ET 8-K
Reverse Stock Split

Medicus Pharma Reverse Stock Split

Medicus Pharma Ltd. announced a fifty-to-one (1-for-50) reverse stock split of its common shares effective October 12, 2026. The consolidation is intended to increase the per-share bid price to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The split was previously authorized by shareholders at the company's annual meeting on June 3, 2026.

8:06 AM ET 8-K
Deal Termination

Medicus Pharma Deal Termination with Ya II Pn, Ltd.

Medicus Pharma Ltd. and Yorkville mutually agreed to terminate their $15.0 million Standby Equity Purchase Agreement (SEPA) effective September 11, 2026. At the time of termination, no shares had been issued and no borrowings were outstanding under the facility, with no fees due from either party.

Counterparty
YA II PN, LTD.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.